Trial
NCT02545283
A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Hoffmann-La Roche
Collaborators
—
Condition
Leukemia, Myeloid, Acute
Intervention
Cytarabine
Why stopped
The study was stopped for futility based on efficacy results at the interim analysis; no unexpected safety findings were observed.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-01-11